TW212138B - - Google Patents

Download PDF

Info

Publication number: TW212138B
Authority: TW; Taiwan
Prior art keywords: nucleus; degassed; guano; pharmaceutical composition; amino
Prior art date: 1988-12-14

Application number

TW78109649A

Other languages

English (en)

Chinese (zh)

Original Assignee

Ciba Geigy Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-14

Filing date

1989-12-13

Publication date

1993-09-01

1989-12-13 Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag

1993-09-01 Application granted granted Critical

1993-09-01 Publication of TW212138B publication Critical patent/TW212138B/zh

Links

239000003112 inhibitor Substances 0.000 claims description 43
239000002777 nucleoside Substances 0.000 claims description 27
239000002515 guano Substances 0.000 claims description 26
150000001875 compounds Chemical class 0.000 claims description 25
-1 2- phenylphenylmethyl Chemical group 0.000 claims description 22
150000003833 nucleoside derivatives Chemical class 0.000 claims description 21
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 18
239000008194 pharmaceutical composition Substances 0.000 claims description 17
239000001257 hydrogen Substances 0.000 claims description 15
229910052739 hydrogen Inorganic materials 0.000 claims description 15
239000000203 mixture Substances 0.000 claims description 15
125000000217 alkyl group Chemical group 0.000 claims description 14
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 13
230000000694 effects Effects 0.000 claims description 11
238000011049 filling Methods 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
229910052736 halogen Inorganic materials 0.000 claims description 8
150000002367 halogens Chemical class 0.000 claims description 8
229940029575 guanosine Drugs 0.000 claims description 7
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
238000011282 treatment Methods 0.000 claims description 7
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 6
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 6
229940079593 drug Drugs 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
238000007872 degassing Methods 0.000 claims description 5
239000007789 gas Substances 0.000 claims description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
230000005764 inhibitory process Effects 0.000 claims description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
OQRXBXNATIHDQO-UHFFFAOYSA-N 6-chloropyridine-3,4-diamine Chemical compound NC1=CN=C(Cl)C=C1N OQRXBXNATIHDQO-UHFFFAOYSA-N 0.000 claims description 4
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
102100036286 Purine nucleoside phosphorylase Human genes 0.000 claims description 4
125000004429 atom Chemical group 0.000 claims description 4
108010009099 nucleoside phosphorylase Proteins 0.000 claims description 4
IHLOTZVBEUFDMD-UUOKFMHZSA-N 7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,2-dioxo-1h-imidazo[4,5-c][1,2,6]thiadiazin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NS(=O)(=O)NC2=O)=C2N=C1 IHLOTZVBEUFDMD-UUOKFMHZSA-N 0.000 claims description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
230000026731 phosphorylation Effects 0.000 claims description 3
238000006366 phosphorylation reaction Methods 0.000 claims description 3
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
206010037549 Purpura Diseases 0.000 claims description 2
241001672981 Purpura Species 0.000 claims description 2
241000700605 Viruses Species 0.000 claims description 2
229910052786 argon Inorganic materials 0.000 claims description 2
229910052757 nitrogen Inorganic materials 0.000 claims description 2
241001430294 unidentified retrovirus Species 0.000 claims description 2
229940122294 Phosphorylase inhibitor Drugs 0.000 claims 6
102000009097 Phosphorylases Human genes 0.000 claims 4
108010073135 Phosphorylases Proteins 0.000 claims 4
150000003212 purines Chemical class 0.000 claims 4
241001164374 Calyx Species 0.000 claims 3
241000219823 Medicago Species 0.000 claims 2
235000017587 Medicago sativa ssp. sativa Nutrition 0.000 claims 2
229910052799 carbon Inorganic materials 0.000 claims 2
125000004432 carbon atom Chemical group C* 0.000 claims 2
210000004907 gland Anatomy 0.000 claims 2
238000006467 substitution reaction Methods 0.000 claims 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
OCLZPNCLRLDXJC-NTSWFWBYSA-N 2-amino-9-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](CO)O1 OCLZPNCLRLDXJC-NTSWFWBYSA-N 0.000 claims 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
241000353097 Molva molva Species 0.000 claims 1
150000001335 aliphatic alkanes Chemical group 0.000 claims 1
210000004727 amygdala Anatomy 0.000 claims 1
230000002079 cooperative effect Effects 0.000 claims 1
230000002550 fecal effect Effects 0.000 claims 1
229910052698 phosphorus Inorganic materials 0.000 claims 1
239000002574 poison Substances 0.000 claims 1
231100000614 poison Toxicity 0.000 claims 1
230000002685 pulmonary effect Effects 0.000 claims 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
229910052704 radon Inorganic materials 0.000 claims 1
SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 claims 1
239000010117 shenhua Substances 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 claims 1
239000002023 wood Substances 0.000 claims 1
101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 49
102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 49
210000004027 cell Anatomy 0.000 description 17
241000725303 Human immunodeficiency virus Species 0.000 description 14
239000004480 active ingredient Substances 0.000 description 13
238000000034 method Methods 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 9
239000004615 ingredient Substances 0.000 description 8
239000007788 liquid Substances 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
241000282412 Homo Species 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
150000002431 hydrogen Chemical class 0.000 description 6
125000003835 nucleoside group Chemical group 0.000 description 6
239000003826 tablet Substances 0.000 description 6
230000009385 viral infection Effects 0.000 description 6
239000002775 capsule Substances 0.000 description 5
238000002512 chemotherapy Methods 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 4
208000031886 HIV Infections Diseases 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 4
230000006378 damage Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 3
WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 3
FNXPTCITVCRFRK-UMMCILCDSA-N 2,8-diamino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound NC1=NC(C(N=C(N)N2)=O)=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O FNXPTCITVCRFRK-UMMCILCDSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
208000037357 HIV infectious disease Diseases 0.000 description 3
206010038997 Retroviral infections Diseases 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000000798 anti-retroviral effect Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
229960002656 didanosine Drugs 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
229930182470 glycoside Natural products 0.000 description 3
150000002338 glycosides Chemical class 0.000 description 3
239000008187 granular material Substances 0.000 description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
238000000465 moulding Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
239000001226 triphosphate Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
244000215068 Acacia senegal Species 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
102000003505 Myosin Human genes 0.000 description 2
108060008487 Myosin Proteins 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108700017801 Purine Nucleoside Phosphorylase Deficiency Proteins 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
238000009739 binding Methods 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000030833 cell death Effects 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
238000002309 gasification Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000000762 glandular Effects 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
238000012856 packing Methods 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
208000001917 purine nucleoside phosphorylase deficiency Diseases 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
210000003625 skull Anatomy 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
235000011178 triphosphate Nutrition 0.000 description 2
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
LULAYUGMBFYYEX-UHFFFAOYSA-M 3-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-M 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
NKGPJODWTZCHGF-KQYNXXCUSA-N 6-thioinosinic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(S)=C2N=C1 NKGPJODWTZCHGF-KQYNXXCUSA-N 0.000 description 1
PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
240000001980 Cucurbita pepo Species 0.000 description 1
235000009852 Cucurbita pepo Nutrition 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
MKRNVBXERAPZOP-UHFFFAOYSA-N Starch acetate Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OC(C)=O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 MKRNVBXERAPZOP-UHFFFAOYSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
BMTWSILZBROYGX-NKWVEPMBSA-N [(2s,5r)-5-(6-oxo-3h-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)O)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BMTWSILZBROYGX-NKWVEPMBSA-N 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
229960005286 carbaryl Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
230000007073 chemical hydrolysis Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000036541 health Effects 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000036737 immune function Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000036039 immunity Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
150000004712 monophosphates Chemical class 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000009377 nuclear transmutation Methods 0.000 description 1
108010028584 nucleotidase Proteins 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
LPNBBFKOUUSUDB-UHFFFAOYSA-M p-toluate Chemical compound CC1=CC=C(C([O-])=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-M 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000002688 persistence Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
208000028529 primary immunodeficiency disease Diseases 0.000 description 1
238000007639 printing Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
101150002764 purA gene Proteins 0.000 description 1
239000002212 purine nucleoside Substances 0.000 description 1
239000000784 purine nucleoside phosphorylase inhibitor Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
229940046729 selective immunosuppressants Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-M succinate(1-) Chemical compound OC(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-M 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000010792 warming Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TW78109649A 1988-12-14 1989-12-13 TW212138B (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US28415388A	1988-12-14	1988-12-14

Publications (1)

Publication Number	Publication Date
TW212138B true TW212138B (da)	1993-09-01

Family

ID=23089064

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW78109649A TW212138B (da)	1988-12-14	1989-12-13

Country Status (2)

Country	Link
TW (1)	TW212138B (da)
ZA (1)	ZA899510B (da)

1989
- 1989-12-13 TW TW78109649A patent/TW212138B/zh active
- 1989-12-13 ZA ZA899510A patent/ZA899510B/xx unknown

Also Published As

Publication number	Publication date
ZA899510B (en)	1990-08-29

Publication	Publication Date	Title
US11266666B2 (en)	2022-03-08	Methods for treating Filoviridae virus infections
US4861759A (en)	1989-08-29	Antiviral compositions and methods
EP1395266B1 (en)	2006-10-04	Use of antiviral nucleoside derivatives for the manufacture of a medicament for the treatment of hepatitis c infections
JP2010202655A (ja)	2010-09-16	チオアラビノフラノシル化合物の製造方法
DK169657B1 (da)	1995-01-09	Anvendelse af visse uracilnucleosider til fremstilling af et lægemiddel mod adenovirusinfektioner samt oftalmiske præparater indeholdende sådanne uracilnucleosider
JPS63239294A (ja)	1988-10-05	新規アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
JPS63290895A (ja)	1988-11-28	抗ウイルスヌクレオシド
AU628113B2 (en)	1992-09-10	2',3'-dideoxypurine nucleoside/purine nucleoside phosphorylase inhibitor combination therapy and composition
US5254539A (en)	1993-10-19	Method of treating HIV with 2',3'-dideoxyinosine
MXPA97002926A (en)	1998-04-01	La-eritrosis nucleosi
PT99434A (pt)	1992-09-30	Processo para a preparacao de composicoes farmaceuticas contendo derivados de xantina
TWI905225B (zh)	2025-11-21	感冒劑及抗病毒劑
JPH03264530A (ja)	1991-11-25	抗レトロウイルス剤
CN107540631A (zh)	2018-01-05	氨基羧酸酯类化合物在治疗寨卡病毒感染方面的应用
US20130059812A1 (en)	2013-03-07	Composition for treating chronic hepatitis b, containing clevudine and adefovir dipivoxil
SG185545A1 (en)	2012-12-28	Composition for treating chronic hepatitis b, containing clevudine and adefovir dipivoxil
CN101511355A (zh)	2009-08-19	(2z)-2-(3,4-二羟基亚苄基)-1-苯并呋喃-3(2h)-酮在制备抗癌药物中的应用
NZ754996B2 (en)	2022-06-28	Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
NZ754996A (en)	2022-03-25	Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
CN106619591A (zh)	2017-05-10	奥昔卡因在制备药物中的用途及药物组合物
CA1333392C (en)	1994-12-06	Antiviral compounds
JPH0544925B2 (da)	1993-07-07
JPS63107924A (ja)	1988-05-12	抗レトロウイルス剤
JPH0551566B2 (da)	1993-08-03
CN112933080A (zh)	2021-06-11	地胆草内酯类化合物在制备具有抗呼吸道合胞病毒作用的药物中的应用